Teva Pharmaceutical Industries (TEVA) shares snapped six straight sessions of gains, as the stock closed 0.4% lower at $33.07 on Thursday.
The generic drugmaker gained about 6% in the preceding six sessions. Overall, the stock rose 47% last year, compared to the over 16% rise in the broader S&P 500 Index.
TEVA is up 5% over the past one month. The stock closed 2% higher on Wednesday at $33.21.
Looking at Seeking Alpha’s Quant Rating, TEVA has a Hold rating with a score of 3.35 out of 5. The company received an A in the prospect of momentum, while it got an F in the growth factor.
Turning to the Wall Street community, 12 analysts gave TEVA a Buy and above; no one gave the stock a Hold recommendation, and one recommended Sell. Seeking Alpha analysts are also cautious and see the stock as a Hold.
Earlier in the week, Israel-based Teva projected lower-than-expected financials for 2026 and a contraction in its business even as its Q4 2025 results exceeded expectations.
Still, Seeking Alpha analyst Motti Sapir is bullish on the stock.
“Unless the pipeline disappoints, regulators come down hard, or debt stops dropping, I see more upside ahead,” Sapir noted.
Another Seeking Alpha analyst, Robert J. Lake also said TEVA’s “Pivot to Growth” plan under new CEO Richard Francis emphasizes cost savings, divestitures, and a focus on innovative drug development for long-term growth.